NEW YORK (GenomeWeb) – Enzo BioChem reported after the close of the market on Monday that its third quarter revenues fell 5 percent year over year.

The firm cited a few issues that resulted in the decline in sales: a medical practice it served decided to internalize its genetic ordering, costing Enzo around $1.9 million; adverse weather; and the loss of an unnamed commercial insurance payor.

For the three months ended April 30, the firm reported total revenues of $25.6 million, down from $27.1 million in Q3 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.